Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF

BACKGROUND: Although oncogenic driver mutations were thought to be mutually exclusive in non‐small cell lung cancer (NSCLC), certain tumors harbor co‐occurring mutations and represent a rare molecular subtype. The evaluation of the clinical features and therapeutic response associated with this NSCL...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuang, Xibin, Zhao, Chao, Li, Jiayu, Su, Chunxia, Chen, Xiaoxia, Ren, Shengxiang, Li, Xuefei, Zhou, Caicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558647/
https://www.ncbi.nlm.nih.gov/pubmed/31016879
http://dx.doi.org/10.1002/cam4.2183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558647/
https://www.ncbi.nlm.nih.gov/pubmed/31016879
http://dx.doi.org/10.1002/cam4.2183

Ejemplares similares